---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-106554"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:24:52.344590+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CEO Cary Claiborne signs new 3-year deal at Adial; bonus target raised to 50%, 350K option grant

## Summary
- New three-year employment agreement effective Dec 5, 2024, replaces prior agreement from Dec 2021.
- Base salary remains $489,250; annual bonus target increased to 50% of base salary.
- Granted 350,000 stock options vesting pro rata monthly over 36 months.
- Agreement provides for severance and change-in-control protections per detailed terms.

## SEC filing metadata
- accession: 0001213900-24-106554
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390024106554/0001213900-24-106554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390024106554/ea0223975-8k_adialpharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-106554
- JSON: https://secwatch.observer/filing/0001213900-24-106554.json
- Plain text: https://secwatch.observer/filing/0001213900-24-106554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.